Compared with BRAF inhibitors alone, combining BRAF and MEK inhibitors have been demonstrated to enhance antitumor activity and delay the emergence of drug resistance in patients who have melanoma harboring BRAF V600E mutations, without increased overall toxicity (Robert et al., 2019). This evidence concerns the gene BRAF and melanoma.